Tags

Type your tag names separated by a space and hit enter

Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Gynecol Oncol. 2001 Sep; 82(3):523-31.GO

Abstract

OBJECTIVE

The present study was planned to measure preoperative levels of soluble urokinase plasminogen activator receptor (suPAR) in plasma from patients with gynecological diseases, and to test for a relationship to clinical and biochemical patient characteristics.

METHODS

Using a specific and sensitive kinetic ELISA, suPAR levels were determined in preoperative citrate plasma samples from 53 ovarian, 34 endometrial, and 30 cervical cancer patients, 17 patients with benign ovarian tumors, and 28 patients with benign endometrial diseases. In addition, suPAR was measured in citrate samples from 31 female blood donors.

RESULTS

suPAR was measurable in all samples. No significant difference was found between plasma suPAR in the blood donors and the patients with benign diseases (P = 0.58). The groups of cancer patients had suPAR levels that were significantly higher than those found in the blood donors (P < 0.0001, P < 0.0001, and P = 0.001 for patients with ovarian, endometrial, and cervical cancer, respectively). In all groups of cancer patients a trend toward increasing suPAR levels with increasing FIGO stage was noted (P = 0.0003, P = 0.02, and P = 0.01 for patients with ovarian, endometrial, and cervical cancer, respectively). Using the median suPAR level to dichotomize the ovarian cancer patients, FIGO stages I-III, a significantly increased risk of progression/relapse was found for patients with high suPAR levels (Hazard ratio (HR) = 3.1, 95% CI: 1.1-8.8, P = 0.03). A multivariate analysis was performed, including suPAR, FIGO stage, and CA-125. Only FIGO stage III compared with FIGO stage I was significant (HR = 15, 95% CI: 1.8-129, P = 0.01). Survival analyses were not performed in the endometrial or cervical cancer patients due to few progressions/relapses during the follow-up period.

CONCLUSION

This study concludes that patients with gynecological cancers have elevated plasma suPAR levels as compared with healthy female blood donors and patients with benign gynecological diseases. In addition, high preoperative plasma levels of suPAR are significantly associated with poor outcome of ovarian cancer patients. However, additional studies are needed to further validate the clinical usefulness of plasma suPAR measurements in the management of ovarian cancer patients.

Authors+Show Affiliations

Finsen Laboratory, Rigshospitalet, DK-2100 Copenhagen, Denmark.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11520150

Citation

Riisbro, R, et al. "Soluble Urokinase Plasminogen Activator Receptor in Preoperatively Obtained Plasma From Patients With Gynecological Cancer or Benign Gynecological Diseases." Gynecologic Oncology, vol. 82, no. 3, 2001, pp. 523-31.
Riisbro R, Stephens RW, Brünner N, et al. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol. 2001;82(3):523-31.
Riisbro, R., Stephens, R. W., Brünner, N., Christensen, I. J., Nielsen, H. J., Heilmann, L., & von Tempelhoff, G. F. (2001). Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecologic Oncology, 82(3), 523-31.
Riisbro R, et al. Soluble Urokinase Plasminogen Activator Receptor in Preoperatively Obtained Plasma From Patients With Gynecological Cancer or Benign Gynecological Diseases. Gynecol Oncol. 2001;82(3):523-31. PubMed PMID: 11520150.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. AU - Riisbro,R, AU - Stephens,R W, AU - Brünner,N, AU - Christensen,I J, AU - Nielsen,H J, AU - Heilmann,L, AU - von Tempelhoff,G F, PY - 2001/8/25/pubmed PY - 2001/9/21/medline PY - 2001/8/25/entrez SP - 523 EP - 31 JF - Gynecologic oncology JO - Gynecol Oncol VL - 82 IS - 3 N2 - OBJECTIVE: The present study was planned to measure preoperative levels of soluble urokinase plasminogen activator receptor (suPAR) in plasma from patients with gynecological diseases, and to test for a relationship to clinical and biochemical patient characteristics. METHODS: Using a specific and sensitive kinetic ELISA, suPAR levels were determined in preoperative citrate plasma samples from 53 ovarian, 34 endometrial, and 30 cervical cancer patients, 17 patients with benign ovarian tumors, and 28 patients with benign endometrial diseases. In addition, suPAR was measured in citrate samples from 31 female blood donors. RESULTS: suPAR was measurable in all samples. No significant difference was found between plasma suPAR in the blood donors and the patients with benign diseases (P = 0.58). The groups of cancer patients had suPAR levels that were significantly higher than those found in the blood donors (P < 0.0001, P < 0.0001, and P = 0.001 for patients with ovarian, endometrial, and cervical cancer, respectively). In all groups of cancer patients a trend toward increasing suPAR levels with increasing FIGO stage was noted (P = 0.0003, P = 0.02, and P = 0.01 for patients with ovarian, endometrial, and cervical cancer, respectively). Using the median suPAR level to dichotomize the ovarian cancer patients, FIGO stages I-III, a significantly increased risk of progression/relapse was found for patients with high suPAR levels (Hazard ratio (HR) = 3.1, 95% CI: 1.1-8.8, P = 0.03). A multivariate analysis was performed, including suPAR, FIGO stage, and CA-125. Only FIGO stage III compared with FIGO stage I was significant (HR = 15, 95% CI: 1.8-129, P = 0.01). Survival analyses were not performed in the endometrial or cervical cancer patients due to few progressions/relapses during the follow-up period. CONCLUSION: This study concludes that patients with gynecological cancers have elevated plasma suPAR levels as compared with healthy female blood donors and patients with benign gynecological diseases. In addition, high preoperative plasma levels of suPAR are significantly associated with poor outcome of ovarian cancer patients. However, additional studies are needed to further validate the clinical usefulness of plasma suPAR measurements in the management of ovarian cancer patients. SN - 0090-8258 UR - https://www.unboundmedicine.com/medline/citation/11520150/Soluble_urokinase_plasminogen_activator_receptor_in_preoperatively_obtained_plasma_from_patients_with_gynecological_cancer_or_benign_gynecological_diseases_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(01)96324-3 DB - PRIME DP - Unbound Medicine ER -